U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Report

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End-use, And Segment Forecasts, 2023 - 2030

Report ID: GVR-1-68038-168-9
Number of Pages: 90
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Table of Contents

Chapter 1. U.S. Clinical Oncology Next Generation Sequencing Market: Methodology and Scope
1.1. Information Procurement
  1.2. Information or Data Analysis
  1.3. Market Scope & Segment Definition
  1.4. Market Model
1.4.1. Market Study, By Company Market Share
Chapter 2. U.S. Clinical Oncology Next Generation Sequencing Market: Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Clinical Oncology Next Generation Sequencing Market: Market Variables, Trends, & Scope
  3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
  3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Reduction in costs for genetic sequencing
  3.2.1.2. Advances in the field of personalized medicine
  3.2.1.3. Increase in prevalence of cancer
3.2.2. Market Restraint Analysis
  3.2.2.1. Lack of computational efficiency for data management
  3.3. Industry Analysis Tools
3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.3.2. Porter's Five Forces Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
  4.1. U.S. clinical Oncology NGS Market: Technology Movement Analysis
  4.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  4.3. Whole Genome Sequencing
4.3.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  4.4. Whole Exome Sequencing
4.4.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  4.5. Targeted Sequencing & Resequencing
4.5.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)
Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
  5.1. U.S. clinical Oncology NGS Market: Workflow Movement Analysis
  5.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  5.3. 5 NGS Pre-Sequencing
5.3.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
  5.4. NGS Sequencing
5.4.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
  5.5. NGS Data Analysis
5.5.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)
Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
  6.1. U.S. clinical Oncology NGS Market: Application Movement Analysis
  6.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  6.3. Screening
6.3.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
6.3.2. Sporadic Cancer
  6.3.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
6.3.3. Inherited cancer
  6.3.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  6.4. Companion Diagnostics
6.4.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  6.5. Other Diagnostics
6.5.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis
  7.1. U.S. clinical Oncology NGS Market: End Use Movement Analysis
  7.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  7.3. Hospitals
7.3.1. Hospitals U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  7.4. Clinics
7.4.1. Clinics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  7.5. Laboratories
7.5.1. Laboratories U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
  8.1. Company Categorization
  8.2. Strategy Mapping
  8.3. Company Profiles/Listing
8.3.1. Illumina, Inc.
  8.3.1.1. Overview
  8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.1.3. Product Benchmarking
  8.3.1.4. Strategic Initiatives
8.3.2. Thermo Fisher Scientific Inc.
  8.3.2.1. Overview
  8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.2.3. Product Benchmarking
  8.3.2.4. Strategic Initiatives
8.3.3. F. Hoffmann-La Roche Ltd
  8.3.3.1. Overview
  8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.3.3. Product Benchmarking
  8.3.3.4. Strategic Initiatives
8.3.4. Agilent Technologies, Inc.
  8.3.4.1. Overview
  8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.4.3. Product Benchmarking
  8.3.4.4. Strategic Initiatives
8.3.5. Myriad Genetics, Inc.
  8.3.5.1. Overview
  8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.5.3. Product Benchmarking
  8.3.5.4. Strategic Initiatives
8.3.6. Beijing Genomics Institute (BGI)
  8.3.6.1. Overview
  8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.6.3. Product Benchmarking
  8.3.6.4. Strategic Initiatives
8.3.7. QIAGEN
  8.3.7.1. Overview
  8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.7.3. Product Benchmarking
  8.3.7.4. Strategic Initiatives
8.3.8. Perkin Elmer, Inc.
  8.3.8.1. Overview
  8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.8.3. Product Benchmarking
  8.3.8.4. Strategic Initiatives
8.3.9. PacBio
  8.3.9.1. Overview
  8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.9.3. Product Benchmarking
  8.3.9.4. Strategic Initiatives
8.3.10. Oxford Nanopore Technologies
  8.3.10.1. Overview
  8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.10.3. Product Benchmarking
  8.3.10.4. Strategic Initiatives
8.3.11. PerkinElmer Inc
  8.3.11.1. Overview
  8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.11.3. Product Benchmarking
  8.3.11.4. Strategic Initiatives
8.3.12. Macrogen, Inc
  8.3.12.1. Overview
  8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  8.3.12.3. Product Benchmarking
  8.3.12.4. Strategic Initiatives

List of Tables

TABLE 1. Cancer Incidence and Mortality, 2018
TABLE 2. U.S. clinical Oncology NGS Market estimates & forecasts
TABLE 3. U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 4. U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 5. U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 6. U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market snapshot
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market trends & outlook
Fig. 9 Market segmentation & scope
Fig. 10 Penetration & growth prospect mapping for application, 2022
Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
Fig. 14 Cost per genome
Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
Fig. 16 Number of new cancer cases in the World, 2022
Fig. 17 Market restraint relevance analysis (Current & future impact)
Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 19 Porter’s Five Forces Analysis
Fig. 20 Strategy framework
Fig. 21 Participant categorization
Fig. 22 U.S. clinical oncology NGS market: Technology outlook key takeaways
Fig. 23 U.S. clinical oncology NGS market: Technology movement analysis
Fig. 24 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 25 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 26 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 27 U.S. clinical oncology NGS market: Workflow outlook key takeaways
Fig. 28 U.S. clinical oncology NGS market: Workflow movement analysis
Fig. 29 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 30 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 31 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
Fig. 32 U.S. clinical oncology NGS market: Application outlook key takeaways
Fig. 33 U.S. clinical oncology NGS market: Application movement analysis
Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 35 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 36 Lifetime cancer risks for common cancers
Fig. 37 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 38 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 39 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 40 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
Fig. 41 Key companies profiled

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.